Polycystic ovary syndrome in women using valproate: A review

References

• Carmina E, Lobo R A. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897–1899
   PubMed Web of Science ®Google Scholar
• Hull M. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987; 1: 235–245
   PubMedGoogle Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 1997; 18: 774–800
   PubMed Web of Science ®Google Scholar
• Conway G, Agrawal R, Betteridge D, Jacobs H. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 37: 119–125
   PubMed Web of Science ®Google Scholar
• Battaglia C, Regnani G, Petraglia F, Primavera M, Salvatori M, Volpe A. Polycystic ovary syndrome: it is always bilateral?. Ultrasound Obstet Gynaecol 1999; 14: 183–187
   PubMedGoogle Scholar
• Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovary syndrome: in defence of the Rotterdam criteria. J Clin Endocrinol Metab 2006; 91: 786–789
   PubMed Web of Science ®Google Scholar
• Taylor A E. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998; 27: 877–902
   PubMed Web of Science ®Google Scholar
• Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. Towards a rational approach. Polycystic ovary syndrome, A Dunaif, J Givens, F Haseltine, G R Merriam. Blackwell Scientific, Boston, MA 1992; pp 152–160.
   Google Scholar
• Rotterdam PCOS Consensus Workshop. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19–25
   Google Scholar
• Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006; 91: 781–785
   PubMed Web of Science ®Google Scholar
• Geisthovel F. A comment on the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine consensus of the polycystic ovarian syndrome. Reprod Biomed Online 2003; 7: 602–605
   Google Scholar
• Azziz R, Woods K S, Reyna R, Key T J, Knochenhauer E S, Yildiz B O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745–2749
   PubMed Web of Science ®Google Scholar
• Asuncion M, Calvo R M, San Millan J L, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434–2438
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Kouli C R, Bergiele A T, Filandra F A, Tsianateli T C, Spina G G, Zapanti E D, Bartzis M I. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006–4011
   PubMed Web of Science ®Google Scholar
• Sackellares J, Crosby C. Long-term efficacy of valproic acid (VPA) in the treatment of absence seizures. Neurology 1980; 30: 420
   Google Scholar
• Margraf J W, Dreifuss F E. Amenorrhea following initiation of therapy with valproic acid [abstract]. Neurology 1981; 31: 151
   Google Scholar
• de Krom M CTFM, Hoppener R JEA, Beukers E. Adverse reactions of sodium valproate: secondary amenorrhea and weight gain [abstract]. Clin Neurol Neurosurg 1985; 81: 66
   Google Scholar
• Maggio B, Giampietro L. Su alcuni effetti endocrinologici del VPA. Boll Lega It Epil 1987; 58/59: 205–206
   Google Scholar
• Jones T H. Sodium valproate-induced menstrual disturbances in young women. Horm Res 1991; 35: 82–85
   Google Scholar
• Isojarvi J IT, Laatikainen T J, Pakarinen A J, Juntunen K TS, Myllyla V V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383–1388
   PubMed Web of Science ®Google Scholar
• Meo R, Bilo L. Polycystic ovary syndrome and epilepsy: a review of the evidence. Drugs 2003; 63: 1185–1227
   PubMedGoogle Scholar
• Herzog A G, Seibel M M, Schomer D, Vaitukaitis J, Geshwind N. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovary syndrome?. Neurology 1984; 34: 1389–1393
   PubMedGoogle Scholar
• Herzog A G, Seibel M M, Schomer D, Vaitukaitis J L, Geshwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 341–346
   PubMed Web of Science ®Google Scholar
• Bilo L, Meo R, Nappi C, Annunziato L, Striano S, Colao A M, Merola B, Buscaino G A. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988; 29: 612–619
   PubMed Web of Science ®Google Scholar
• Bilo L, Meo R, Valentino R, Buscaino G A, Striano S, Nappi C. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil Steril 1991; 55: 705–711
   PubMed Web of Science ®Google Scholar
• Herzog A G, Seibel M M, Schomer D L, Vaitukaitis J L, Geshwind N. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 347–350
   PubMed Web of Science ®Google Scholar
• Isojarvi J IT, Laatikainen T J, Knip M, Pakarinen A J, Juntunen K TS, Myllyla V V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579–584
   PubMed Web of Science ®Google Scholar
• Murialdo G, Galimberti C A, Magri F, Sampaolo P, Copello F, Gianelli M V, Gazzerro E, Rollero A, Deagatone C, Manni R, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997; 20: 519–526
   PubMed Web of Science ®Google Scholar
• Murialdo G, Galimberti C A, Gianelli M V, Rollero A, Polleri A, Copello F, Magri F, Ferrari E, Sampaolo P, Manni R, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998; 21: 52–58
   PubMed Web of Science ®Google Scholar
• Vainonpaa L, Rattya J, Knip M, Tapanainen J, Pakarinen A J, Lanning P, Tekay A, Myllyla V V, Isojarvi J I. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999; 45: 444–450
   Google Scholar
• Bauer J, Jarre A, Klingmuller D, Elger C. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000; 41: 167
   Google Scholar
• Khatami R, Henrich W, Bauer M, Heinze T, Schmitz B. The significance of polycystic ovaries in women with epilepsy under treatment with antiepileptic drugs: preliminary results of a prospective observational study [abstract]. Epilepsia 2000; 41: 143
   Google Scholar
• Bilo L, Meo R, Valentino R, Di Carlo C, Striano S, Nappi C. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 2001; 86: 2950–2956
   PubMed Web of Science ®Google Scholar
• Isojarvi J IT, Tauboll E, Pakarinen A J, van Parys J, Rattya J, Harbo H, Dale P O, Fauser B C, Gjerstad L, Koivunen R, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001; 111: 290–296
   PubMed Web of Science ®Google Scholar
• Stephen L, Kwan P, Shapiro D, Dominiczak M, Brodie M. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001; 42: 1002–1006
   PubMed Web of Science ®Google Scholar
• Chakravarty A. Preliminary observations on valproate and cystic ovaries. Neurology India 2002; 50: 106–107
   Google Scholar
• Luef G, Abraham I, Trinka E, Alge A, Windisch J, Daxenbichler G, Unterberger I, Seppi K, Lechleitner M, Kramer G, et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 2002; 48: 91–102
   PubMed Web of Science ®Google Scholar
• Luef G, Abraham I, Haslinger M, Trinka E, Seppi K, Unterberger I, Alge A, Windisch J, Lechleitner M, Bauer G. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002; 249: 835–841
   PubMed Web of Science ®Google Scholar
• Betts T, Yarrow H, Dutton N, Greenhill L, Rolfe T. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 2003; 12: 323–329
   PubMed Web of Science ®Google Scholar
• Otoom S, Nusier M, Hasan M, Hadidi H, Samawi R, Younes A, Darweesh M, Boulatova N R. Association of polycystic ovaries with the use of valproic acid in Jordanian patients. Clin Drug Invest 2003; 23: 527–532
   Google Scholar
• de Vries L, Karasik A, Landau Z, Phillip M, Kiviti S, Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia 2007; 48: 470–477
   PubMed Web of Science ®Google Scholar
• Hamed S A, Hamed E A, Shokry M, Omar H, Abdellah M M. The reproductive conditions and lipid profile in females with epilepsy. Acta Neurol Scand 2007; 115: 12–22
   PubMed Web of Science ®Google Scholar
• Prabhakar S, Sahota P, Kharbanda P S, Siali R, Jain V, Lal V, Khurana D. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Epilepsia 2007; 48: 1371–1377
   PubMed Web of Science ®Google Scholar
• El Khayat H A, Abd El-Basset F Z, Tomoum H Y, Tohamy S M, Zaky A A, Mohamed M S, Hakky S M, El Barbary N S, Nassef N M. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. Epilepsia 2004; 45: 1106–1115
   Google Scholar
• Laidlaw J. Catamenial epilepsy. Lancet 1956; 2: 1235–1237
   Google Scholar
• Logothetis J, Harner R, Morrell F, Torres F. The role of estrogens in catamenial exacerbations of epilepsy. Neurology 1959; 9: 352–360
   PubMed Web of Science ®Google Scholar
• Trampuz V, Dimitrijevic M, Kryzanovski J. [Role of epilepsy in the pathogenesis of ovarian dysfunction]. Neuropsihijatrija 1975; 23: 179–183
   Google Scholar
• Backstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976; 54: 321–347
   PubMed Web of Science ®Google Scholar
• Rosciszewska D, Dudkiewicz J, Blecharz A. Changes in cytohormonal cervical swabs in epileptic women. Neurol Neurochir Pol 1976; 10: 255–259
   PubMedGoogle Scholar
• Jensen I, Vaernet K. Temporal lobe epilepsy: follow-up investigation of 74 temporal lobe resected patients. Acta Neurochir 1977; 37: 173–200
   PubMedGoogle Scholar
• Mattson R H, Kamer J A, Caldwell B V, Cramer J A. Seizure frequency and the menstrual cycle: a clinical study [abstract]. Epilepsia 1981; 22: 242
   Web of Science ®Google Scholar
• Skierska E, Leszczynska-Bystrzanowska J, Gajewski A K. [Risk analysis of menstrual disorders in young women from urban population]. Przegl Epidemiol 1996; 50: 467–474
   Google Scholar
• Rasgon N L, Altshuler L L, Fairbanks L, Elman S, Bitran J, Labarca R, Saad M, Kupka R, Nolen W A, Frye M A, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246–259
   PubMed Web of Science ®Google Scholar
• Rasgon N L, Reynolds M F, Elman S, Saad M, Frye M A, Bauer M, Altshuler L L. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord 2005; 89: 217–225
   PubMed Web of Science ®Google Scholar
• Joffe H, Cohen L S, Suppes T, McLaughlin W L, Lavori P, Adams J M, Hwang C H, Hall J E, Sachs G S. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59: 1078–1086
   PubMed Web of Science ®Google Scholar
• Joffe H, Cohen L S, Suppes T, Hwang C H, Molay F, Adams J M, Sachs G S, Hall J E. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 2006; 60: 1378–1381
   PubMed Web of Science ®Google Scholar
• O'Donovan C, Graves J, Kusumakar V. Prevalence rates of self-reported menstrual abnormalities and clinical hyperandrogenism of women taking divalproex for bipolar mood disorder [abstract no. 89]. Proceedings of Third Conference on Bipolar Disorder; 1999 June 17–19. Pittsburgh, PA
   Google Scholar
• O'Donovan C, Kusumakar V, Graves G, Bird D. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63: 322–330
   PubMed Web of Science ®Google Scholar
• McIntyre R S, Mancini D A, McCann S, Srinivasan J, Kennedy S H. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003; 5: 28–35
   PubMed Web of Science ®Google Scholar
• Joffe H, Hall J E, Cohen L S, Taylor A E, Baldessarini R J. A putative relationship between valproic acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harv Rev Psychiatry 2003; 11: 99–108
   PubMed Web of Science ®Google Scholar
• Akdeniz F, Taneli F, Noyan A, Yuncu Z, Vahip S. Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women?. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 115–121
   Google Scholar
• Bilo L, Meo R. Epilepsy and polycystic ovary syndrome: where is the link?. Neurol Sci 2006; 27: 221–230
   Google Scholar
• Egger J, Brett E. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed) 1981; 283: 577–581
   PubMed Web of Science ®Google Scholar
• Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65–69
   PubMed Web of Science ®Google Scholar
• Corman C, Leung N, Guberman A. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997; 24: 240–244
   PubMedGoogle Scholar
• Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230–232
   PubMed Web of Science ®Google Scholar
• Breum L, Astrup A, Gram L, Andersen T, Stokholm K, Christensen N, Werdelin L, Madsen J. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 666–670
   PubMed Web of Science ®Google Scholar
• Vorum H, Gram L, Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity. Epilepsy Res 1993; 16: 55–64
   PubMedGoogle Scholar
• Roste L, Tauboll E, Isojarvi J, Pakarinen A J, Huhtaniemi I, Knip M. Effects of chronic valproate treatment on reproductive endocrine function in female and male Wistar rats. Reprod Toxicol 2002; 16: 767–773
   PubMed Web of Science ®Google Scholar
• Tauboll E, Roste L, Svalheim S, Gjerstad L. Disorders of reproduction in epilepsy – what can we learn from animal studies?. Seizure 2008; 17: 120–126
   PubMed Web of Science ®Google Scholar
• Jacobsen N, Halling-Sorensen B, Birkved F. Inhibition of human aromatase complex (CYP19) by antiepiletic drugs. Toxicol In Vitro 2008; 22: 146–153
   PubMed Web of Science ®Google Scholar
• Nelson-Degrave V L, Wickenheisser J K, Cockrell J E, Wood J R, Legro R S, Strauss JF I II, McAllister J M. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004; 145: 799–808
   PubMed Web of Science ®Google Scholar
• Wood J R, Nelson-Degrave V L, Jansen E, McAllister J M, Mosselman S, Strauss J F, III. Valproate-induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. Physiol Genomics 2005; 20: 233–243
   PubMed Web of Science ®Google Scholar
• Pylvanen V, Knip M, Pakarinen A J, Kotila M, Turkka J, Isojarvi J IT. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002; 43: 514–517
   PubMed Web of Science ®Google Scholar
• Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 2006; 47: 1460–1464
   PubMed Web of Science ®Google Scholar
• Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002; 17: 265–268
   PubMed Web of Science ®Google Scholar
• Ding M P, Bao Y Y, Chen Z, Liu Z R, Xu L L. [Insulin resistance in epileptic patients during treatment of valproic acid]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004; 33: 216–218
   Google Scholar
• Aydin K, Serdaroglu A, Okuyaz C, Bideci A, Gucuyener K. Serum insulin, leptin, and neuropeptide Y levels in epileptic children treated with valproate. J Child Neurol 2005; 20: 848–851
   PubMed Web of Science ®Google Scholar
• Tan H, Orbak Z, Kantarci M, Kocak N, Karaca L. Valproate-induced insulin resistance in prepubertal girls with epilepsy. J Pediatr Endocrinol Metab 2005; 18: 985–989
   Google Scholar
• Meo R, Bilo L, Nappi C, Tommaselli A P, Valentino R, Nocerino C, Striano S, Buscaino G A. Derangement of the hypothalamic GnRH pulse generator in women with epilepsy. Seizure 1993; 2: 241–252
   PubMedGoogle Scholar
• Klipstein K G, Goldberg J F. Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study. J Affect Disord 2006; 91: 205–209
   PubMed Web of Science ®Google Scholar